Drug developer Karo Bio has started using Elsevier’s Reaxys and Reaxys Medicinal Chemistry solutions to help its chemists identify and priortise drug compounds for further research and development.
Elsevier, which publishes scientific and medical information, said Reaxys Medical Chemistry will help Karo Bio to cut research time by 20% by providing access to journal articles and patents coupled with its search engine.
Maria Sjöberg, CSO at Karo Bio, said the solution will make results more relevant in a single search compared with other services: "Not only do our chemists have access to more data, including biological as well as chemical information, but the content is more applicable to their research. We expect the availability of the Reaxys Medicinal Chemistry information alone will reduce research and development time by approximately 20%."
Juergen Swienty-Busch, head of product management at Reaxys, said: "Karo Bio has a unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals."
Reaxys and Reaxys Medicinal Chemistry, which combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning, are part of Elsevier Life Science Solutions.
